FEV1 Cancer Research Results

FEV1, Forced Expiratory Volume in 1 Second: Click to Expand ⟱

Source:

Type:

FEV1

Full Name: Forced Expiratory Volume in 1 Second

Definition: FEV1 is the volume of air that can be forcibly exhaled during the first second of a forced expiratory maneuver. It is one of the principal spirometric measurements used to assess airflow obstruction.

Asthma relevance: FEV1 may decrease during bronchoconstriction or poorly controlled asthma and increase following effective bronchodilation or improved disease control. Bronchodilator reversibility in FEV1 is commonly used in asthma assessment.

Direction:
FEV1 ↓ = generally adverse / increased airflow obstruction
FEV1 ↑ = generally beneficial when reduced by asthma

Typical relationship:
Bronchoconstriction ↑ → Airway Resistance ↑ → FEV1 ↓

Scientific Papers found: Click to Expand⟱

7936-

TQ,

Effect of Nigella sativa supplementation on lung function and inflammatory mediators in partly controlled asthma: a randomized controlled trial

Trial,

Asthma,

*Dose↝, 1 and 2 g/day of N sativa, respectively, for 3 months along with maintenance inhaled therapy.
*FEV1↑, FEF25-75% and FEV1 (% predicted) increased significantly (P<.05) at both 6 and 12 weeks in the NS-2 group.
*PEF↑, FEF25-75% and FEV1 (% predicted) increased significantly (P<.05) at both 6 and 12 weeks in the NS-2 group.
*IgE↓, FeNO and serum IgE decreased significantly after 12 weeks in both the NS-1 and NS-2 groups vs baseline
*IFN-γ↑, Both doses of N sativa produced a significant increase in the serum IFN-γ at 12 weeks vs baseline
*eff↑, Significantly fewer patients had exacerbations in the NS-1 group
*IL4∅, The levels of IL-4, IL-10, IL-17A and the eotaxins did not change significantly in any of the three groups at any of the follow up visits.
*IL10∅,
*IL17∅,

7935-

TQ,

Nigella sativa Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial

Trial,

Asthma,

*Dose↝, NSO capsules 500 mg twice daily for 4 weeks were used as a supplementary treatment in a randomized, double-blind, placebo-controlled trial in asthmatics
*eff↑, NSO group showed a significant improvement in mean Asthma Control Test score 21.1 (standard deviation = 2.6) versus 19.6 (standard deviation = 3.7) (p = 0.044) and a significant reduction in blood eosinophils by -50 (-155 to -1) versus 15 (-60 to 87)
*Eos↓,
*FEV1↑, NSO improved forced expiratory volume in 1 second as percentage of predicted value by 4 (-1.25 to 8.75) versus 1 (-2 to 5) but non-significant (p = 0.170)

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

NA, unassigned(tgid=0) ⓘ

Eos↓, 1, FEV1↑, 2, IgE↓, 1, PEF↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↑, 1, IL10∅, 1, IL17∅, 1, IL4∅, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2, eff↑, 2,
Total Targets: 10

Scientific Paper Hit Count for: FEV1, Forced Expiratory Volume in 1 Second

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells